UK Accepts All 44 AI Healthcare Regulation Recommendations

The UK government on Tuesday, 6 October 2026, accepted all 44 recommendations of the National Commission into the Regulation of AI in Healthcare and set out how it plans to deliver them across the UK. Alongside the response, the Medicines and Healthcare products Regulatory Agency (MHRA) opened applications for the third phase of AI Airlock, its regulatory sandbox for AI-enabled medical devices. The GOV.UK announcement says a full implementation roadmap covering every recommendation will be published by Spring 2027.

What the UK government response commits to

The commission, set up by the MHRA in September 2025 as an independent, non-statutory body, published its recommendations on 10 September 2026 after evidence gathering that involved more than 12,000 people, according to the government.

The government response states that because AI has developed so much since the UK Medical Devices Regulations 2002 were drafted, the existing device regulations are not fit for purpose. It groups the work into ten priority areas under three themes: proportionate lifecycle regulation, system-wide responsibility and safe management, and trust, transparency and predictability.

Under the first theme, the MHRA will consult on a new approach to how software and AI products qualify as medical devices and how they are classified, with the consultation due by Spring 2027. The response says the agency will then use secondary legislation to update the definition of a medical device, which may include carve-outs for certain administrative, general wellbeing and decision support software.

The MHRA has also committed to issue draft guidance by December 2026 on managing changes to AI-enabled devices as they adapt over time. The response says it will explore Predetermined Change Control Plans, staged authorisation pathways that allow earlier NHS use under close supervision while real-world evidence is gathered, and wider use of regulatory sandboxes, working with NICE and its counterparts in the devolved nations.

AI Airlock Phase 3 targets post-market surveillance

The government says AI Airlock has secured three more years of funding after its pilot and second phase. Phase 3 focuses on post-market surveillance and regulation across a device's working life, reflecting one of the commission's central conclusions: that AI-enabled devices should be assessed and monitored throughout their working life instead of relying too heavily on one-time assessments.

The AI Airlock application page lists three priority topics. The first is ongoing assurance, including how manufacturers can capture deployment-context factors such as local infrastructure, workflow integration and data quality. The second is surveillance in settings with varying levels of oversight, such as remote use, direct-to-consumer products or systems with higher autonomy. The third is how manufacturers communicate performance, safety, updates and rollbacks to regulators, providers, professionals and patients.

A webinar for prospective applicants is scheduled for 22 October 2026 at 10:00, and the government says the first wave of participants will be selected in November 2026. The application page says the window stays open year-round, with applications reviewed in scheduled waves.

Accountability, redress and patient information

Beyond device rules, the response assigns work across the health system. DHSC and NHS England will build an AI Readiness Toolbox to help healthcare organisations assess whether they are ready to adopt AI tools, and professional regulators and education bodies will work on AI literacy for clinicians.

A working group including DHSC, the MHRA, the Care Quality Commission, NHS Resolution and the Professional Standards Authority will clarify how responsibility is shared among manufacturers, providers, professionals and regulators. The response says DHSC will work with the Patient Safety Commissioner so that patients have access to redress when AI-enabled care falls below the expected standard. DHSC has also said it will support a consistent, proportionate approach to informing patients about how AI is used in their care.

To oversee delivery, the government is creating a cross-system Programme Board with representatives from the devolved administrations. According to the response, it will meet quarterly, report each quarter to the Life Sciences Delivery Board and publish annual progress updates once the roadmap is out.

How ministers, the MHRA and devolved nations responded

Health innovation minister James Frith said the government wants patients to benefit from AI but that "innovation must never come at the expense of patient safety." MHRA chief executive Lawrence Tallon called the commission's report "a clear and ambitious blueprint" for getting AI products to patients safely and quickly.

Professor Alastair Denniston, who chaired the commission, said the response showed the government had listened to the more than 12,000 patients, clinicians and members of the public who shaped the recommendations. Deputy chair Professor Henrietta Hughes, the Patient Safety Commissioner for England, singled out the commitments on monitoring AI in use, patient involvement and routes to redress.

The devolved governments also responded. Scotland's health secretary, Angela Constance, said Scotland will set out its own response in due course and pointed to existing interim guidance on AI in health and social care. Wales and Northern Ireland welcomed the recommendations and said they would keep working with the MHRA. Steve Lee of the industry body ABHI said aligning with international best practice will be key to implementation.

PromptCrates has also followed US regulators' work on AI devices, including the FDA's TEMPO pilot for AI chronic-care tools and its request for feedback on generative AI medical devices. In the UK, it has reported on research such as the Imperial and British Heart Foundation AI ECG work on heart disease detection.

• GOV.UK: Government backs recommendations of NHS doctors-led AI Commission
• GOV.UK: Government response to the National Commission's recommendations
• GOV.UK: AI Airlock Phase 3 application
• GOV.UK: National Commission into the Regulation of AI in Healthcare recommendations
• PromptCrates: FDA TEMPO pilot lets AI care tools reach patients early
• PromptCrates: FDA seeks feedback on generative AI medical devices
• PromptCrates: AI ECG flags heart failure in under two seconds